Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockadeDavid Ciccone, Christine Loh, Fu‐Shan Kuo et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 8
Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumorsRobert Svensson, Peter J. Tummino, Scott Boiko et al.|Cancer Research|2025Cited by 5
Discovery and characterization of novel inhibitors of CTP synthase 1 (CTPS1) for the treatment of autoimmune and inflammatory diseaseJoshua McElwee, Peter J. Tummino, K. D. Kreutter et al.|The Journal of Immunology|2023Cited by 2
685 A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor modelDavid Ciccone, Neelu Kaila, Vad Lazari et al.|Regular and Young Investigator Award Abstracts|2020Cited by 1
Abstract 1649: Mechanistic understanding of HPK1 inhibition on enhanced human T cell activation and tumor immunity in a syngeneic modelDavid Ciccone, Neelu Kaila, Vad Lazari et al.|Cancer Research|2021Cited by 1